Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries

The American Journal of Cardiology
T S TsangPaul Wayne Armstrong

Abstract

We evaluated allergic reactions in 20,201 patients randomized to the streptokinase arms of The Global Utilization of Streptokinase and t-PA (Tissue Plasminogen Activator) in Occluded Coronary Arteries (GUSTO-I) trial, and tested the hypothesis that patients with streptokinase allergy would exhibit higher mortality. After adjusting for baseline variables and time of death, we found comparable coronary patency, left ventricular function, mortality, and bleeding complications between patients with versus those without streptokinase allergy.

References

Sep 2, 1993·The New England Journal of Medicine·UNKNOWN GUSTO investigators

❮ Previous
Next ❯

Citations

May 18, 2011·Critical Care : the Official Journal of the Critical Care Forum·Pascal AugustinPhilippe Montravers
Dec 6, 2005·Irish Journal of Medical Science·J P McRedmondD J Fitzgerald
Dec 21, 2000·Current Atherosclerosis Reports·S Sundararajan, L B Morgenstern
Feb 10, 2007·International Journal of Cardiology·Gabriel Tatu-ChiţoiuNicoleta Caea
Aug 10, 2002·Acta medica Austriaca·Ch Pechlaner
Aug 30, 2008·Applied Psychophysiology and Biofeedback·Alan G Glaros
Feb 15, 2011·American Journal of Therapeutics·Lucas C RosierePeter S Pang
Aug 29, 2020·BMC Cardiovascular Disorders·Małgorzata DybowskaWitold Tomkowski
Jun 1, 2021·Interventional Cardiology Clinics·Chayakrit KrittanawongHani Jneid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

© 2021 Meta ULC. All rights reserved